Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 14, p.2390-3295 (2008)


2008, Acute Disease, Adolescent, Adult, Aminoglycosides, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Asparaginase, Child, Child, Preschool, Clinical Research Division, Cytarabine, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Infant, Leukemia, Myeloid, Male, MITOXANTRONE, Survival Rate


While gemtuzumab ozogamicin (GTMZ) is commonly used in the treatment of acute myeloid leukemia (AML) in combination with standard chemotherapy agents, the pediatric maximum-tolerated dose (MTD) of GMTZ in combination with chemotherapy has not been determined.